Aurobindo Pharma Q2FY26 Concall Decoded: From Pen-G to Peptides — Big Chemistry, Bigger Confidence

When a pharma company runs fermentation, biosimilars, and global M&As all in one quarter, it’s either chaos or choreography. For Aurobindo, it was both — controlled chaos with a confident smile. Tariff petitions, FDA inspections, and bioreactor bragging all made it to the Q2FY26 call. The CFO’s calm hid some caffeine — and the CEO’s biosimilar roadmap had more acronyms than a biotech dictionary.
If science were cinema, Aurobindo’s sequel is “Penicillin Strikes Back.” Stick around — this plot thickens faster than a fermentation broth.

At a Glance

• Revenue ₹8,286 cr (+6% YoY): Growth without drama — for once.
• EBITDA ₹1,678 cr (20.3% margin): Margin’s back in fighting shape.
• PAT ₹848 cr: Not bad for a quarter juggling a dozen divisions.
• Formulations ₹7,325 cr (88% of revenue): Pills pay the bills.
• Europe ₹2,480 cr (+18% YoY): Euro boom continues — no Brexit blues.
• API ₹961 cr: Still the silent sibling.
• Pen-G plant 40–50% utilization: Brewing confidence, literally.
• R&D spend ₹414 cr (5% of sales): Still burning cash to build science.

Management’s Key Commentary

“Revenue grew 6% YoY, driven by strong U.S. and European performance.”
(Translation: America buys, Europe pays, and India prays.)

“EBITDA margin at 20.3% — operating leverage and discipline at play.”
(A fancy way of saying we didn’t overspend this quarter.)

“Pen-G operations began July 1; yields improving and breakeven near.”
(Fermenters are finally doing more than bubbling hope.)

“Europe to cross €1 billion revenue milestone by FY26-end.”
(Brexit who? They’re too busy billing.)

“Dayton plant commercial by FY27, Raleigh awaiting FDA clearance.”
(FDA still typing: ‘Your inspection will be scheduled shortly.’)

“Biosimilars pipeline accelerating with Denosumab, Omalizumab, Tocilizumab.”
(Even the names sound like a science quiz 😏)

“We’re confident of maintaining 20–21% margins for FY26.”
(Confidence levels: sky-high; caution levels: optional.)

Numbers Decoded